Compare Charles River Laboratories Intl. Inc (CRL) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Equinor ASA — how do they compare? Charles River Laboratories Intl. Inc trades at $287.27 (market cap $13.46B), while Equinor ASA trades at $40.88 (market cap $97.58B). The key difference: Equinor ASA is far larger — about 7.2× Charles River Laboratories Intl. Inc's market cap, and Equinor ASA pays a 3.81% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | EQNR | |
|---|---|---|
Market Cap | $13.46B | $97.58B |
Sector | Health | Energy |
52-Week High | $282.00 | $42.40 |
52-Week Low | $145.57 | $22.41 |
Enterprise Value | $16.30B | $106.28B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Equinor (EQNR) trades at $40.865, down 0.3% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth of 40% year-over-year. Valuation ratios remain attractive with a P/E of 11.09 and EV/EBITDA of 2.3. Recent news highlights a 22.2% monthly rally, driven by higher energy prices and output, alongside ongoing share buybacks and consistent dividend payments.
The outlook is cautiously positive, supported by robust cash flow and strategic investments in production growth. However, risks include volatile energy prices, execution challenges in portfolio adjustments, and a high tax burden impacting net margins. Analyst sentiment is mixed, with 30% buy ratings but majority holds, reflecting valuation concerns after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
